In particular, EphA2 was expressed at different levels in individual leukemic samples but the significant expression in a proportion of clinical samples bearing the 11q23 chromosomal (MLL) re-arrangement, suggested that EphA2 might be a therapeutic target in human MLL-driven leukemia. The gene discussed is KMT2A; the disease is leukemia.